Evidence map›Paper›PMID 32435886›Full record

ArticleVirchows Archiv : an international journal of pathology2020

Prognostic relevance of the loss of stromal CD34 positive fibroblasts in invasive lobular carcinoma of the breast.

Christina C Westhoff, Paul Jank, Christian O Jacke, Ute-Susann Albert, Schokufe Ebrahimsade, Peter J Barth, Roland Moll

Open access · hybridAbstract read
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Pitfalls in the Histological Diagnosis of Morphologic Variants of Invasive Lobular Carcinoma of the Breast.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025
    Review
  4. Article
  5. E-Cadherin-Mediated Cell-Cell Adhesion and Invasive Lobular Breast Cancer.Advances in experimental medicine and biology · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Christina C WesthoffInstitute of Pathology, Philipps University of Marburg and University Hospital Giessen and Marburg GmbH, Baldingerstrasse, 35043, Marburg, Germany. westhoff@med.uni-marburg.de.ORCID https://orcid.org/0000-0002-6812-3563
Paul JankInstitute of Pathology, Philipps University of Marburg and University Hospital Giessen and Marburg GmbH, Baldingerstrasse, 35043, Marburg, Germany.
Christian O JackeDepartment of Gynecology and Obstetrics, Breast Center Regio, Philipps University of Marburg and University Hospital Giessen and Marburg GmbH, 35043, Marburg, Germany.
Ute-Susann AlbertDepartment of Gynecology and Obstetrics, Breast Center Regio, Philipps University of Marburg and University Hospital Giessen and Marburg GmbH, 35043, Marburg, Germany.
Schokufe EbrahimsadeInstitute of Pathology, Philipps University of Marburg and University Hospital Giessen and Marburg GmbH, Baldingerstrasse, 35043, Marburg, Germany.
Peter J BarthGerhard Domagk Institute of Pathology, University Hospital Muenster, 48149, Muenster, Germany.
Roland MollInstitute of Pathology, Philipps University of Marburg and University Hospital Giessen and Marburg GmbH, Baldingerstrasse, 35043, Marburg, Germany.
Philipps University of Marburg · DEUniversity Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD34+ fibroblasts are constitutive stromal components of virtually all organs, including the mammary stroma, being involved in matrix synthesis, antigen presentation, and tumor-associated stromal remodeling. The most common subtype of invasive breast carcinoma, invasive carcinoma of no special type (IBC-NST), is known for its stromal loss of CD34+ fibroblasts while acquiring alpha smooth muscle actin-positive (α-SMA+) myofibroblasts, i.e., cancer-associated fibroblasts (CAF), whereas invasive lobular carcinoma (ILC) displays partial preservation of CD34+ fibroblasts. The aim of this study was to evaluate the prognostic relevance of stromal CD34+ fibroblasts and α-SMA+ myofibroblasts in an extended collection of ILC. A total of 133 cases of ILC, primarily resected between 1996 and 2004 at University Hospital Marburg, were examined semiquantitatively for stromal content of CD34+ fibroblasts and α-SMA+ myofibroblasts. Partial preservation of CD34+ fibroblasts in the tumor stroma of ILC was confirmed. Absence of CD34+ fibroblasts in the tumor stroma significantly correlated with the presence of α-SMA+ myofibroblasts (p = 0.010), positive lymph node status (p = 0.004), and pN stage (p = 0.006). Stromal loss of CD34+ fibroblasts was significantly associated with lower overall and disease-free survival rates (p = 0.012 and 0.013, respectively). Multivariate analysis adjusted for pT and pN stage revealed stromal loss of CD34+ fibroblasts as independent prognostic parameter (p = 0.05). To our knowledge, this is the first report defining prognostically relevant stromal subtypes of ILC with long-term follow-up. Future research targeting the potential diagnostic and therapeutic implications of CD34+ fibroblasts and CAF in breast cancer, especially ILC, is a promising field of interest.

Indexed as

ActinsAntigens, CD34Biomarkers, TumorBreast NeoplasmsCarcinoma, LobularDisease-Free SurvivalFemaleFibroblastsHumansImmunohistochemistryLymphatic MetastasisMyofibroblastsNeoplasm StagingStromal CellsTime FactorsACTA2 protein, humanActinsAntigens, CD34Biomarkers, TumorBreastCancer-associated fibroblastsCD34FibroblastsFibrocytesInvasive lobular carcinomaNodal status

Identifiers

PMID32435886
PMCPMC7581514
OpenAlexW3027719703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.